Biomica Announces Advancement to Pre-Clinical Studies in its Inflammatory Bowel Disease Program
This is the second program to enter pre-clinical studies; In addition, Prof. David T. Rubin, joins Biomica as a Scientific & Medical Advisor
REHOVOT, Israel, Oct. 2, 2019 /PRNewswire/ -- Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) and (TASE: EVGN), announces today the initiation of pre-clinical studies for BMC321 & BMC322, two rationally-designed microbial consortia aimed to reduce inflammation for the treatment of Inflammatory Bowel Disease (IBD). Biomica's program aims to develop a novel microbiome-based drug for IBD that triggers multiple mechanisms for the reduction of intestinal inflammation. This is the second program Biomica has advanced to pre-clinical studies, following the initiation of preclinical studies in its oncology program.
IBD including ulcerative colitis and Crohn's disease are chronic, debilitating, non-infectious, inflammatory diseases of the digestive tract. The incidence of IBD is increasing and the overall response to current available treatments is limited to 40-60%.
The role of the microbiome in IBD etiology is well established and it is now recognized as an important target for development of new treatments for these diseases. Led by Prof. Yehuda Ringel (CSO) Biomica's IBD drug development program has taken a unique scientific approach targeting multiple microbial-related mechanisms that underlay the intestinal inflammation of IBD. The discovery process implements PRISM, a proprietary high-resolution computational microbiome analysis platform based on Evogene's CPB platform. PRISM is designed to process big data, enabling the identification of microbial functions and strains. Biomica's computational approach allows for a thorough understanding of the functional elements of the microbiome that are relevant to the human condition and enables a rational design of live bacterial consortia based on the smallest number of strains bearing multiple desired activities. The approach is expected to yield maximal therapeutic effects while minimizing the potential for adverse effects.
Biomica's IBD discovery campaign involved implementing a large comparative analysis of hundreds of stool samples obtained from IBD patients. This analysis resulted in the detection of an array of microbial functions associated with states of inflammation and remission as well as in the identification of specific bacterial strains carrying these functions. These strains and functions have been combined to design Biomica's consortia BMC321 & BMC322. The tolerability and efficacy of BMC321 & BMC322 are currently being evaluated in pre-clinical studies using multiple IBD animal models.
In addition to the advancement of the IBD program, Biomica is pleased to welcome Prof. David T. Rubin, a renowned gastroenterologist who specializes in the research and treatment of IBD as a scientific and medical advisor. Prof. Rubin is Section Chief, Gastroenterology, Hepatology and Nutrition and a Co-Director of the Digestive Diseases Center at the University of Chicago. Prof. Rubin is the Chair-elect of the Crohn's & Colitis Foundation's National Scientific Advisory Committee. In addition to numerous awards and honors, Prof. Rubin is the editor of a best-selling book on IBD, and an author or coauthor of many peer-reviewed articles on treatment and management of IBD, cancer in IBD. His current research includes a variety of collaborative studies related to the microbiome and intestinal disease, for more information please see @IBDMD on Twitter. Prof. Rubin joins Prof. Y. Ringel, Prof. B. Sartor, Prof. J. Versalovic and Prof. W. De-Vos in supporting the company's upcoming steps towards its pre-clinical and clinical development processes.
Dr. Elran Haber, Biomica CEO, stated: "We are very pleased our second program has advanced from the computational stage to pre-clinical studies. We believe our drug candidate consortia designed to target the underlying causes of inflammation associated with Inflammatory Bowel Disease will provide a new form of therapy for this chronic and devastating condition. Our advancement to pre-clinical trials is based on the outcomes of unique computational insights provided by Biomica's PRISM platform. We look forward to sharing initial results in 2020. Additionally, I would like to welcome Prof. Rubin. We look forward to working together and expect his vast experience in this field will significantly contribute to this program."
Prof. R. Balfour Sartor, Biomica Scientific Board member, stated: "It has been well established that the intestinal microbiome and the diminished microbial diversity are implicated in the pathogenesis of IBD. I believe that Biomica's novel approach, targeting microbial functions that impact a combination of pathways to reduce inflammation, have the potential to make a true impact on the treatment of IBD patients."
About BMC321 & BMC322
Developed as Live Bacterial Products (LBPs), BMC321 & BMC322 are rationally-designed LBP consortia comprised of unique microbes that harbor multiple functional capabilities with the potential to reduce gut mucosal inflammation.
Rationally-designed consortia are multi-strain products designed to restore diversity and specific functionality to a microbial community with individually selected, cultured bacteria.
Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing a dedicated Computational Predictive Biology platform (CPB). Biomica aims to identify and characterize disease-related microbiome entities, and to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders.
Biomica is a subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN). For more information, please visit www.biomicamed.com
About Evogene Ltd.:
Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company developing novel products for major life science markets through the use of a unique computational predictive biology (CPB) platform incorporating deep scientific understandings and advanced computational technologies. Today, this platform is utilized by the Company to discover and develop innovative products in the main following areas (via subsidiaries or divisions): ag-chemicals, ag-biologicals, seed traits, human microbiome based therapeutics and medical cannabis. Each subsidiary or division establishes its product pipeline and go-to-market, as demonstrated in their collaborations with world-leading companies such as BASF, Bayer, Corteva, and ICL. For more information, please visit www.evogene.com.
About Evogene's Computational Predictive Biology (CPB) Platform
Evogene's CPB platform has been designed for the in silico (computational) prediction and prioritization of genes, proteins, microbes and small molecules based on multiple attributes that will be key to successful development and commercialization of novel life-science based products. Successfully addressing these multiple product attributes at the beginning of the discovery process, rather than one at a time during the development phase, is expected to reduce the time and cost of a program, but much more importantly, increase the probability of reaching a successful outcome. Furthermore, the CPB capabilities are also directed to optimization of products and product candidates, based on computational and experimental results.
Cautionary Statement About Forward-Looking Statements
This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Biomica may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Biomica's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene and Biomica disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Investor Relation and Public Relations Manager
US Investor Relations:
View original content to download multimedia:http://www.prnewswire.com/news-releases/biomica-announces-advancement-to-pre-clinical-studies-in-its-inflammatory-bowel-disease-program-300929572.html
Company Codes: NASDAQ-NMS:EVGN, TelAviv:EVGN